The promising potential to live longer through KIMMTRAK
KIMMTRAK® (tebentafusp-tebn) is the first and only FDA-approved treatment that, in a randomized clinical trial, was proven to significantly extend overall survival for HLA-A*02:01–positive adults with uveal melanoma that cannot be removed by surgery or has spread.
HLA-A, human leukocyte antigen-A.
The promising potential to live longer through KIMMTRAK
KIMMTRAK® (tebentafusp-tebn) is the first and only FDA-approved treatment that, in a randomized clinical trial, was proven to significantly extend overall survival for HLA-A*02:01–positive adults with uveal melanoma that cannot be removed by surgery or has spread.
HLA-A, human leukocyte antigen-A.
Ask your doctor if KIMMTRAK is right for you. Learn more.
The largest international, phase 3 trial of 378 HLA-A*02:01–positive adult patients with metastatic uveal melanoma compared KIMMTRAK with investigator’s choice of checkpoint inhibitors (pembrolizumab or ipilimumab) or chemotherapy (dacarbazine).
KIMMTRAK was studied in a phase 3 trial of HLA-A*02:01–positive adult patients with metastatic uveal melanoma
a Median is the middle number from all patients in the study.
KIMMTRAK showed significant* improvement in median overall survival compared to the other treatments studied in the trial (pembrolizumab, ipilimumab, or dacarbazine) in HLA-A*02:01–positive adult patients with metastatic uveal melanoma.
* KIMMTRAK was proven to extend median overall survival by 6 months in patients with metastatic uveal melanoma (21.7 months with KIMMTRAK vs 16.0 months with the other treatments studied). Median is the middle number from all patients in the study.
KIMMTRAK is a breakthrough new therapy indicated for the treatment of HLA-A*02:01–positive adult patients with uveal melanoma that has spread to other parts of the body or can’t be removed with surgery.
KIMMTRAK is not chemotherapy or radiation therapy—it is an immunotherapy† treatment designed to mobilize and activate the T cells of your own immune system to fight uveal melanoma tumor cells.‡
KIMMTRAK is given once weekly in the form of an IV infusion over 15-20 minutes.
When you receive KIMMTRAK:
Side effects such as cytokine release syndrome or rash are most likely to occur during the first 3 doses.
Looking to download information about metastatic uveal melanoma and treatment with KIMMTRAK?
Knowing what side effects to expect and when they are most likely to occur can help you prepare.
The most common side effects of KIMMTRAK include:
These are not all the possible side effects of KIMMTRAK; please see the Patient Information for more information. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 (1-800-332-1088).
The KIMMTRAK CONNECT team is here to help you know what to expect and how to manage your treatment experience and to provide encouragement. Every patient is unique. KIMMTRAK CONNECT provides services and support tailored to your specific needs.
KIMMTRAK is a prescription medicine used to treat HLA-A*02:01–positive adults with uveal melanoma that cannot be removed by surgery or has spread.
What is the most important information I should know about KIMMTRAK?
KIMMTRAK can cause serious side effects that can be severe or life threatening and usually happen within the first three infusions, including:
Tell your healthcare provider right away if you get any of these symptoms. Your healthcare provider will check for these problems during treatment with KIMMTRAK. Your healthcare provider may temporarily stop or completely stop your treatment with KIMMTRAK if you have severe side effects.
See "KIMMTRAK can cause other serious side effects" for more information.
Before receiving KIMMTRAK, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
These are not all the side effects possible with KIMMTRAK.
Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 (1-800-332-1088).
Please read the accompanying Patient Information Leaflet before you receive KIMMTRAK and discuss any questions you have with your healthcare provider.
Please see KIMMTRAK Patient Information.
What is the most important information I should know about KIMMTRAK?
KIMMTRAK can cause serious side effects that can be severe or life threatening and usually happen within the first three infusions, including:
KIMMTRAK is a prescription medicine used to treat HLA-A*02:01–positive adults with uveal melanoma that cannot be removed by surgery or has spread.